Mangalam Drugs And Organics Limited — Results, 07-08-2025: Integrated Filing- Financial

**Revenue Performance:**

Mangalam Drugs and Organics Ltd. has announced a board meeting on August 7, 2025, where it approved the financial results for the quarter ended June 30, 2025. The company reported a significant drop in total revenue from operations, which stood at Rs 57.21 Cr for Q1 FY26, down sharply by 25.21% year-on-year compared to Rs 76.49 Cr in Q1 FY25. The company operates in a single segment: Manufacturing of Bulk Drugs.

**Profitability and EPS:**

This steep decline in revenue led to a net loss of Rs 13.80 Cr for the quarter, a significant reversal from a net profit of Rs 2.68 Cr in the same quarter last year. Basic Earnings Per Share (EPS) turned negative at Rs (8.72) from Rs 1.70 previously.

**Operational Costs:**

While Cost of Materials Consumed decreased to Rs 23.34 Cr from Rs 40.53 Cr, and Other Expenses also saw a reduction, these cost controls were insufficient to offset the substantial revenue fall. Finance costs increased marginally, further impacting the bottom line.

**Management Commentary / Strategic Outlook:**

A key update is the ongoing Scheme of Merger by Absorption involving Mangalam Laboratories Pvt Ltd and Shri JB Pharma Pvt Ltd with Mangalam Drugs and Organics. A meeting for creditors and shareholders is set for August 12, 2025, to discuss this corporate action.

**Final Takeaway:**

The latest results indicate weak momentum, primarily due to a substantial fall in sales. Investors should monitor the progress of the merger as a potential future business development that could impact the company's structure and operations.